Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 2070264

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 2070264

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Opportunities And Strategies To 2035

PUBLISHED:
PAGES: 377 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4490
PDF & Excel (Site License)
USD 6490
PDF & Excel (Enterprise License)
USD 8490

Add to Cart

Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics refer to the products and services used to diagnose, monitor, and manage a digestive disorder in which the pancreas fails to secrete sufficient digestive enzymes, primarily lipase, amylase, and protease into the small intestine. This deficiency results in impaired digestion and malabsorption of fats, proteins, and carbohydrates, leading to symptoms such as steatorrhea, weight loss, abdominal discomfort, bloating, and nutritional deficiencies.

The EPI therapeutics and diagnostics market consist of sales by entities (organizations, sole traders and partnerships) of EPI therapeutics and diagnostics serves pediatric, adult, and geriatric populations affected by underlying conditions such as chronic pancreatitis, pancreatic cancer, diabetes, and post-pancreatectomy status. These therapeutic and diagnostic solutions are used when patients present with clinical signs of malabsorption or when pancreatic disorders are suspected or confirmed. Management is typically long-term and often lifelong, depending on disease etiology.

The global EPI therapeutics and diagnostics market was valued at $4,267.3 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 7.00%.

Rising Demand For Personalized Medicine

The rising demand for personalized medicine fuelled the growth of the EPI therapeutics and diagnostics in the historic period. Recognizing that EPI can arise from diverse etiologist, such as cystic fibrosis, chronic pancreatitis, or pancreatic surgery, each requiring a nuanced approach, clinicians began leveraging advanced diagnostic tools to assess individual pancreatic function more precisely. This demand for personalization drove the adoption of sophisticated tests like fecal elastase-1 and coefficient of fat absorption (CFA) assays, which allow for accurate quantification of pancreatic insufficiency and fat malabsorption in individual patients. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Among these approvals, seven were cancer drugs, while three targeted other diseases and conditions. Therefore, the rising demand for personalized medicine drove the growth of the EPI therapeutics and diagnostics market.

Biotechnology, Genomics & Precision Medicine

Major companies in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are increasingly prioritizing biotechnology, genomics, and precision medicine to enable more accurate disease detection and personalized treatment strategies for pancreatic and gastrointestinal disorders. These initiatives use advanced biomarker-based diagnostics, molecular testing technologies, and targeted clinical data analysis to enable more precise identification of pancreatic dysfunction and improved monitoring of digestive health conditions. For example, in July 2025, QuidelOrtho Corporation, a US-based in vitro diagnostics company specializing in clinical chemistry and immunoassay technologies, in collaboration with BUHLMANN Laboratories AG, a Switzerland-based diagnostics company focused on biomarker assays, announced the availability of the BUHLMANN fCAL turbo and fPELA turbo assays on VITROS Systems, particle-enhanced turbidimetric immunoassays designed to measure fecal calprotectin and fecal pancreatic elastase, supporting rapid, non-invasive detection of inflammatory bowel disease and pancreatic insufficiency and enabling more precise diagnostic evaluation of gastrointestinal conditions.

The global EPI therapeutics and diagnostics market is highly concentrated, with large players operating in the market. The top 10 competitors in the market made up 58.82% of the total market in 2024.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for pancreatic insufficiency (EPI) therapeutics and diagnostics? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The pancreatic insufficiency (EPI) therapeutics and diagnostics market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider pancreatic insufficiency (EPI) therapeutics and diagnostics market; and compares it with other markets.

The report covers the following chapters

  • Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segments, key products, supply chain and market attractiveness scoring and analysis.
  • Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market
  • Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
  • Global Market Size And Growth Global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional And Country Analysis- Historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison by region and country.
  • Market Segmentation- Contains the market values (2020-2025) (2025-2030, 2035F) and analysis for each segment by type, by distribution channel and by end user in the market. Historic (2020-2025) and forecast (2025-2030) and (2030-2035) market values and growth and market share comparison by region market.
  • Regional Market Size and Growth- Regional market size (2025), historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Other Major And Innovative Companies Details on the company profiles of other major and innovative companies in the market.
  • Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
  • Competitive Dashboard- Briefs on competitive dashboard of major players.
  • Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
  • Recent Developments Information on recent developments in the market covered in the report.
  • Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions And Recommendations- This section includes recommendations for exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
  • Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

  • 1) By Type: Therapies; Diagnostics
  • 2) By Distribution Channel: Direct Tender; Retail Pharmacy; Third-Party Distributor; Other Distribution Channels
  • 3) By End User: Hospitals; Specialty Clinics; Homecare; Diagnostic Centers; Research And Academic Institutes; Other End Users
  • Companies Mentioned: Abbvie Inc. (Creon); Nestle Health Science SA (Zenpep); Abbott Laboratories; Nordmark Arzneimittel GmbH & Co. KG; DiaSorin S.p.A.
  • Countries: China; Australia; India; Indonesia; Japan; South Korea;USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia; Taiwan
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time-series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; EPI therapeutics and diagnostics indicators comparison.
  • Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Product Code: PH4MEPIE01_O26Q1

Table of Contents

1 Executive Summary

  • 1.1 Dashboard

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

  • 6.1 General Market Definition
  • 6.2 Summary
  • 6.3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Definition And Segmentations
  • 6.4 Market Segmentation By Type (Therapies And Diagnostics)
  • 6.5 Market Sub-Segmentation By Therapies (Nutritional Management And Pancreatic Enzyme Replacement Therapy (PERT))
  • 6.6 Market Sub-Segmentation By Diagnostics (Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS) And Computerized Tomography (CT) Scanning)
  • 6.7 Market Sub-Segmentation of Therapies, By Drug Type (Generic And Branded)
  • 6.8 Market Segmentation By Distribution Channel (Direct Tender, Retail Pharmacy, Third-Party Distributor, And Other Distribution Channels)
  • 6.9 Market Segmentation By End User (Gaming, Entertainment, Banking, Financial Services And Insurance (BFSI), Information Technology (IT) And Telecommunication, Education, Automotive, Advertisement, Health And Sports And Other Industries)

7 EPI Therapeutics And Diagnostics Market, Overview Of Key Products/Services

  • 7.1 Global EPI Therapeutics And Diagnostics Market Attractiveness Scoring And Analysis
    • 7.1.1 Overview Of Market Attractiveness Framework
    • 7.1.2 Quantitative Scoring Methodology
    • 7.1.3 Market Attractiveness Scoring And Interpretation
    • 7.1.4 Factor-Wise Evaluation
    • 7.1.5 Strategic Implications And Recommendations

8 Major Market Trends

  • 8.1 Key Technologies & Future Trends
    • 8.1.1 Biotechnology, Genomics & Precision Medicine
    • 8.1.2 Industry 4.0 And Intelligent Manufacturing
    • 8.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 8.1.4 Artificial Intelligence And Autonomous Intelligence
    • 8.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
  • 8.2 Major Trends
    • 8.2.1 Enhanced Affordability Program Supports Commercially Insured EPI Patients
    • 8.2.2 Advancements in Next-Generation Pancreatic Enzyme Replacement Therapies (PERT)
    • 8.2.3 Strategic Collaboration Accelerates Non-Porcine Enzyme Innovation In EPI

9 EPI Therapeutics And Diagnostics Growth Analysis And Strategic Analysis Framework

  • 9.1 Global EPI Therapeutics And Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors)
    • 9.1.1 Political
    • 9.1.2 Economic
    • 9.1.3 Social
    • 9.1.4 Technological
    • 9.1.5 Environmental
    • 9.1.6 Legal
  • 9.2 Analysis Of End User (B2B)
    • 9.2.1 Hospitals
    • 9.2.2 Specialty Clinics
    • 9.2.3 Homecare
    • 9.2.4 Diagnostic Center
    • 9.2.5 Research And Academic Institutes
    • 9.2.6 Other End Users

10 Global EPI Therapeutics And Diagnostics Market Size And Growth Analysis

  • 10.1 Historic Market Growth, 2020 - 2025, Value ($ Million)
    • 10.1.1 Market Drivers 2020 - 2025
    • 10.1.2 Market Restraints 2020 - 2025
  • 10.2 Forecast Market Growth, 2025 - 2030, 2035F Value ($ Million)
  • 10.3 Forecast Growth Contributors/Factors
    • 10.3.1 Quantitative Growth Contributors
    • 10.3.2 Drivers
    • 10.3.3 Restraints

11 Global EPI Therapeutics And Diagnostics Total Addressable Market (TAM) Analysis

  • 11.1 Definition And Scope of Total Addressable Market (TAM)
  • 11.2 Methodology And Assumptions
    • 11.2.1 Total Addressable Market for the EPI Therapeutics And Diagnostics Market - Business to Customer (B2C)
    • 11.2.2 TAM Comparison Analysis

12 Global EPI Therapeutics And Diagnostics Market Segmentation

  • 12.1 Global EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 12.2 Global EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 12.3 Global EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 12.4 Global EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 12.5 Global EPI Therapeutics And Diagnostics Market, Segmentation By Distribution Channel, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 12.6 Global EPI Therapeutics And Diagnostics Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 12.7 Global EPI Therapeutics And Diagnostics Market, Sub-Segmentation Of Nutritional Management, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 12.8 Global EPI Therapeutics And Diagnostics Market, Sub-Segmentation Of Pancreatic Enzyme Replacement Therapy (PERT), By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

13 EPI Therapeutics And Diagnostics Market, Regional and Country Analysis

  • 13.1 Global EPI Therapeutics And Diagnostics Market, By Region, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 13.2 Global EPI Therapeutics And Diagnostics Market, By Country, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

14 Asia-Pacific Market

  • 14.1 Asia-Pacific Market Summary
  • 14.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 14.3 Asia Pacific EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.4 Asia Pacific EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.5 Asia Pacific EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.6 Asia Pacific EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.7 China Market
    • 14.7.1 China Market Summary
    • 14.7.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
    • 14.7.3 China EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.7.4 China EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.7.5 China EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.7.6 China EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.8 India Market
    • 14.8.1 India EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.8.2 India EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.8.3 India EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.8.4 India EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.9 Japan Market
    • 14.9.1 Japan Market Summary
    • 14.9.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
    • 14.9.3 Japan EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.9.4 Japan EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.9.5 Japan EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.9.6 Japan EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.10 Australia Market
    • 14.10.1 Australia EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.10.2 Australia EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.10.3 Australia EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.10.4 Australia EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.11 South Korea Market
  • 14.12 South Korea Market Summary
    • 14.12.1 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
    • 14.12.2 South Korea EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.12.3 South Korea EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.12.4 South Korea EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.12.5 South Korea EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 14.13 Taiwan Market
  • 14.14 Taiwan Market Summary
    • 14.14.1 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
    • 14.14.2 Taiwan EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.14.3 Taiwan EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.14.4 Taiwan EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 14.14.5 Taiwan EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

15 South East Asia Market

  • 15.1 South East Asia Market Summary
  • 15.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
    • 15.2.1 South East Asia EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 15.2.2 South East Asia EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 15.2.3 South East Asia EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 15.2.4 South East Asia EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 15.3 Indonesia Market
    • 15.3.1 Indonesia EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 15.3.2 Indonesia EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 15.3.3 Indonesia EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 15.3.4 Indonesia EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

16 Western Europe Market

  • 16.1 Western Europe Market Summary
  • 16.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 16.3 Western Europe EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.4 Western Europe EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.5 Western Europe EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.6 Western Europe EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.7 UK Market
    • 16.7.1 UK EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.7.2 UK EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.7.3 UK EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.7.4 UK EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.8 Germany Market
    • 16.8.1 Germany EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.8.2 Germany EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.8.3 Germany EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.8.4 Germany EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.9 France Market
    • 16.9.1 France EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.9.2 France EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.9.3 France EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.9.4 France EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.10 Italy Market
    • 16.10.1 Italy EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.10.2 Italy EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.10.3 Italy EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.10.4 Italy EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 16.11 Spain Market
    • 16.11.1 Spain EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.11.2 Spain EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.11.3 Spain EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 16.11.4 Spain EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

17 Eastern Europe Market

  • 17.1 Eastern Europe Market Summary
  • 17.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 17.3 Eastern Europe EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 17.4 Eastern Europe EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 17.5 Eastern Europe EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 17.6 Eastern Europe EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 17.7 Russia Market
    • 17.7.1 Russia EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 17.7.2 Russia EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 17.7.3 Russia EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 17.7.4 Russia EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

18 North America Market

  • 18.1 North America Market Summary
  • 18.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 18.3 North America EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 18.4 North America EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 18.5 North America EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 18.6 North America EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 18.7 USA Market
    • 18.7.1 USA Market Summary
    • 18.7.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
    • 18.7.3 USA EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 18.7.4 USA EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 18.7.5 USA EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 18.7.6 USA EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 18.8 Canada Market
    • 18.8.1 Canada Market Summary
    • 18.8.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
    • 18.8.3 Canada EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 18.8.4 Canada EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 18.8.5 Canada EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 18.8.6 Canada EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

19 South America Market

  • 19.1 South America Market Summary
  • 19.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 19.3 South America EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 19.4 South America EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 19.5 South America EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 19.6 South America EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 19.7 Brazil Market
    • 19.7.1 Brazil EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 19.7.2 Brazil EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 19.7.3 Brazil EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
    • 19.7.4 Brazil EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

20 Middle East Market

  • 20.1 Middle East Market Summary
  • 20.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 20.3 Middle East EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 20.4 Middle East EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 20.5 Middle East EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 20.6 Middle East EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

21 Africa Market

  • 21.1 Africa Market Summary
  • 21.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
  • 21.3 Africa EPI Therapeutics And Diagnostics Market, Segmentation By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 21.4 Africa EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Therapies, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 21.5 Africa EPI Therapeutics And Diagnostics Market, Sub-Segmentation By Diagnostics, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
  • 21.6 Africa EPI Therapeutics And Diagnostics Market, Sub-Segmentation of Therapies, By Drug Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

22 Competitive Landscape And Company Profiles

  • 22.1 EPI Therapeutics And Diagnostics Market Competitive Landscape And & Market Share 2024
    • 22.1.1 Top 10 Companies (Ranked by revenue/share)
  • 22.2 Company Profiles
  • 22.3 Abbvie Inc (Creon) (Company Overview, Products and Services, Business Strategy, Financial Overview)
  • 22.4 Nestle Health Science SA (Zenpep) (Company Overview, Products and Services, Business Strategy, Financial Overview)
  • 22.5 Abbott Laboratories (Company Overview, Products and Services, Business Strategy, Financial Overview)
  • 22.6 Nordmark Arzneimittel GmbH & Co. KG (Company Overview, Products and Services, Business Strategy, Financial Overview)
  • 22.7 DiaSorin S.p.A. (Company Overview, Products and Services, Business Strategy, Financial Overview)

23 Other Major And Innovative Companies

  • 23.1 Organon Group of Companies (COTAZYM) (Company Overview, Products and Services)
  • 23.2 Vivus Inc. (Company Overview, Products and Services)
  • 23.3 Quest Diagnostics Incorporated (Company Overview, Products and Services)
  • 23.4 Genova Diagnostics (Company Overview, Products and Services)
  • 23.5 Alcresta Therapeutics Inc. (Company Overview, Products and Services)
  • 23.6 Certest Biotec SL (Company Overview, Products and Services)
  • 23.7 ALPCO Diagnostics Co. (Company Overview, Products and Services)
  • 23.8 BUHLMANN Laboratories AG (fPELA(R) turbo test) (Company Overview, Products and Services)
  • 23.9 Digestive Care, Inc. (PERTZYE) (Company Overview, Products and Services)
  • 23.10 Bioserv Diagnostics GmbH (R-Biopharm Group) (Company Overview, Products and Services)
  • 23.11 ChiRhoClin Inc. (Company Overview, Products and Services)
  • 23.12 EagleBioscience Inc. (Company Overview, Products and Services)
  • 23.13 Vytala (Company Overview, Products and Services)
  • 23.14 Adalvo (Company Overview, Products and Services)
  • 23.15 Codexis, Inc. (Company Overview, Products and Services)

24 Competitive Benchmarking

25 Competitive Dashboard

26 EPI Therapeutics And Diagnostics Market - Company Scoring Matrix

  • 26.1 Innovation & Brand Leaders
  • 26.2 Brand-Driven Traditionalists
  • 26.3 Niche or Regional Followers
  • 26.4 Emerging Innovators

27 Upcoming Startups In the EPI Therapeutics And Diagnostics Market

28 Recent Developments In The EPI Therapeutics And Diagnostics Market

  • 28.1 Clinical Trial Advancement for Enzyme-Based Therapy in Pancreatitis-Associated EPI
  • 28.2 Expansion of Pancreatin Delayed-Release Therapies For Exocrine Pancreatic Insufficiency

29 Opportunities And Strategies

  • 29.1 Global EPI Therapeutics And Diagnostics Market In 2030 - Countries Offering Most New Opportunities
  • 29.2 Global EPI Therapeutics And Diagnostics Market In 2030 - Segments Offering Most New Opportunities
  • 29.3 Global EPI Therapeutics And Diagnostics Market In 2030 - Growth Strategies
    • 29.3.1 Market Trend Based Strategies
    • 29.3.2 Competitor Strategies

30 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Conclusions And Recommendations

  • 30.1 Conclusions
  • 30.2 Recommendations
    • 30.2.1 Product
    • 30.2.2 Place
    • 30.2.3 Price
    • 30.2.4 Promotion
    • 30.2.5 People

31 Appendix

  • 31.1 Geographies Covered
  • 31.2 Market Data Sources
  • 31.3 Research Methodology
  • 31.4 Currencies
  • 31.5 The Business Research Company
  • 31.6 Copyright and Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!